Nebenwirkungen · Enhertu
Enhertu 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-144530 · Präparat HOS-099200
Enhertu 5.4 mg/kg in combination with pertuzumab In patients treated with Enhertu 5.4 mg/kg in combination with pertuzumab in clinical studies (n = 431), neutropenia was reported in 49% of patients and 24.8% had Grade 3 or 4 events. Median time to first onset was 42 days (range: 1 day to 36.8 months) and median duration of the first event was 20 days (range: 1 day to 27.6 months). Febrile neutropenia was reported in 2.6% of patients and one event (0.2%) was Grade 5 (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:27:00Z · SHA-256 3c4c744afc1ef29bbcad254e39bd7fd8b4be34bb4ddecf254258c2ab2c9863c8 · Passage 9c5a3257a55da0ba3fe625065ee8b8423cd130cd74c115eb4bac73c6fb7e1e3d · Zeichen 26986–27474 im Abschnitt